Better Virological Outcomes Among People Living With Human Immunodeficiency Virus (HIV) Initiating Early Antiretroviral Treatment (CD4 Counts ≥500 Cells/µL) in the HIV Prevention Trials Network 071 (PopART) Trial in South Africa

Abstract

Background There have been concerns about reduced adherence and human immunodeficiency virus (HIV) virological suppression (VS) among clinically well people initiating antiretroviral therapy (ART) with high pre-ART CD4 cell counts. We compared virological outcomes by pre-ART CD4 count, where universal ART initiation was provided in the HIV Prevention Trials Network 071 (PopART) trial in South Africa prior to routine national and international implementation. Methods This prospective cohort study included adults initiating ART at facilities providing universal ART since January 2014. VS (<400 copies/mL), confirmed virological failure (VF) (2 consecutive viral loads >1000 copies/mL), and viral rebound were compared between participants in strata of baseline CD4 cell count. Results The sample included 1901 participants. VS was ≥94% among participants with baseline CD4 count ≥500 cells/µL at all 6-month intervals to 30 months. The risk of an elevated viral load (≥400 copies/mL) was independently lower among participants with baseline CD4 count ≥500 cells/µL (3.3%) compared to those with CD4 count 200–499 cells/µL (9.2%) between months 18 and 30 (adjusted relative risk, 0.30 [95% confidence interval, .12–.74]; P = .010). The incidence rate of VF was 7.0, 2.0, and 0.5 per 100 person-years among participants with baseline CD4 count <200, 200–499, and ≥500 cells/µL, respectively (P < .0001). VF was independently lower among participants with baseline CD4 count ≥500 cells/µL (adjusted hazard ratio [aHR], 0.23; P = .045) and 3-fold higher among those with baseline CD4 count <200 cells/µL (aHR, 3.49; P < .0001). Conclusions Despite previous concerns, participants initiating ART with CD4 counts ≥500 cells/µL had very good virological outcomes, being better than those with CD4 counts 200–499 cells/µL. Clinical Trials Registration NCT01900977.

Factors associated with antiretroviral treatment failure among people living with HIV on antiretroviral therapy in resource-poor settings: a systematic review and metaanalysis

“…Likewise, the association between low CD4 count and treatment failure was also observed using four cohort studies [ 36 , 38 , 45 , 46 ]. Results presented in Fig.…”

Virological suppression and clinical management in response to viremia in South African HIV treatment program: A multicenter cohort study

“…Although the results of these studies are important, they are likely not representative of clinical care in large-scale treatment programs. Recently, some efforts to characterize suppression in larger populations of patients, using clinical database systems and population-based surveys, have been undertaken, but these remain of relatively modest size and scope [41][42][43][44][45]. Centralized laboratory databases have enabled cross-sectional analyses of VL data at a much larger scale and can be used to infer some clinical variables such as treatment start date and between-clinic transfer [21,[46][47][48].…”

HIV treatment outcomes among people with initiation CD4 counts >500 cells/µL after implementation of Treat All in South African public clinics: a retrospective cohort study

“…For example, early ART initiation was acceptable in a South African research cohort [19], and adherence levels were high among patients initiated at CD4 counts >500 cells/µL in the Treatment as Prevention trial in KwaZulu‐Natal [20]. However, in a sub‐study of three South African clinics within the HPTN 071 (PopART) trial, patients initiated at CD4 counts >500 cells/µL had worse attrition [21], but comparable or better viral load outcomes compared to patients with lower CD4 counts [22]. The authors suggest that the novelty of providing ART for people with CD4 counts >500 cells/µL, before it became national policy, may have contributed to attrition in this group.…”